Novartis AG (SWX:NOVN)
96.18
+0.16 (0.17%)
Jun 27, 2025, 5:35 PM CET
Novartis AG Revenue
Novartis AG had revenue of $13.62B USD in the quarter ending March 31, 2025, with 12.38% growth. This brings the company's revenue in the last twelve months to $53.22B, up 11.50% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
$53.22B
Revenue Growth
+11.50%
P/S Ratio
3.96
Revenue / Employee
$701.37K
Employees
75,883
Market Cap
186.07B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 62.40B |
Lonza Group AG | 6.57B |
Alcon | 8.77B |
Galderma Group AG | 4.02B |
Sandoz Group AG | 9.41B |
Straumann Holding AG | 2.50B |
Sonova Holding AG | 3.87B |
Ypsomed Holding AG | 748.87M |
Novartis AG News
- 1 day ago - Final Trades: Novartis, Sixth Street, Amazon and the IYF - CNBC
- 1 day ago - Novartis in deal with ProFound for cardiovascular disease therapies - Seeking Alpha
- 1 day ago - ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease - GlobeNewsWire
- 2 days ago - Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma - Benzinga
- 2 days ago - Novartis completes acquisition of Regulus Therapeutics - GlobeNewsWire
- 2 days ago - Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? - Investor's Business Daily
- 2 days ago - Novartis: A SWAN Worth Owning - Seeking Alpha
- 3 days ago - Novartis announces expiration of Regulus Therapeutics tender offer - GlobeNewsWire